Associate Professor Evan Ingley heads the Cell Signalling group, which has an interest in understanding the signalling networks or "information highways" of both normal and diseased cells. Many of the new generation anti-cancer/leukaemia drugs disrupt these signalling networks and bring about a "normalization" of protein interactions. One of the underlying control principles of these processes is that of regulated protein-protein interactions. A/Prof Ingley's group focuses on an enzyme, Lyn, which modifies proteins and through this process mediates specific protein interactions that can enhance or hinder particular cellular processes including cell growth, shape, movement, differentiation and death.
Abstracts this author is presenting: